Holen Sie sich die Stockscreener-App
1.21
0.83%
0.01
Io Biotech Inc Aktie (IOBT) Neueste Nachrichten
Io Biotech Inc Files For Resale Of Up To 5.6 Million Shares Of Common Stock By The Selling StockholdersSEC Filing - marketscreener.com
IOBT Investors: Understanding Stockholder Sales Impact | IOBT Stock News - GuruFocus
IO Biotech Announces Participation in Cowen 6th Annual Oncology Innovation Summit and Jefferies Global Healthcare Conference - The Manila Times
Cancer Vaccine Developer IO Biotech Headlines Two Major Healthcare Conferences This Summer - Stock Titan
Is NIO Stock Set for a Comeback? Fundamentals Say Yes - The Globe and Mail
Q2 Earnings Forecast for IO Biotech Issued By HC Wainwright - Defense World
Why Alphabet Stock Ticked Higher Today - The Globe and Mail
IO Biotech Advances Cancer Vaccine Trials in Q1 2025 - TipRanks
IO Biotech price target raised to $14 from $12 at H.C. Wainwright - Yahoo Finance
Why American Eagle Stock Plummeted After Earnings - The Globe and Mail
IO Biotech, Inc. SEC 10-Q Report - TradingView
IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights - The Manila Times
Electricity-Breathing E. coli Could Power the Future of Biotech - Securities.io
‘We’re Delivering Real Progress Toward Profitability:’ Is Plug Power Stock a Buy, Sell, or Hold After Earnings? - The Globe and Mail
IO Biotech (IOBT) Projected to Post Quarterly Earnings on Tuesday - Defense World
Renaissance Technologies LLC Raises Stake in IO Biotech, Inc. (NASDAQ:IOBT) - Defense World
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of IO Biotech, Inc. (NASDAQ: IOBT) and Encourages IOBT Shareholders to Contact the Firm - ACCESS Newswire
From “Super Skeptical” Beginnings, a New Immune-Modulatory Vaccine Awaits Phase 3 Results - AJMC
Will Top-Line Improvement Benefit Palantir in Q1 Earnings? - The Globe and Mail
Top 5 Lab-Grown Meat Stocks to Invest In (May 2025) - Securities.io
IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025 - The Manila Times
IO Biotech's Co-Founder Mads Hald Andersen Highlights Advances in Cancer Vaccine Research at 2025 AACR Annual Meeting - Nasdaq
Breakthrough Cancer Vaccine Technology Reveals New Approach to Reprogram Tumor Environment - Stock Titan
IO Biotech unveils promising vaccine preclinical data By Investing.com - Investing.com Canada
IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170 - The Manila Times
Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting - The Manila Times
New Cancer Vaccine Data Shows Powerful Immune Response in Multiple Tumors | IOBT Stock News - Stock Titan
Short Sellers Gave Up on These 3 Names Recently - The Globe and Mail
4 Cheap Stocks With Solid Fundamentals to Offset Market Uncertainty - The Globe and Mail
Cotton Extending Strength to Friday Morning - The Globe and Mail
Healthcare Services (HCSG) Receives a Hold from William Blair - The Globe and Mail
3 Reasons AMTM is Risky and 1 Stock to Buy Instead - The Globe and Mail
Nano One 2025 Annual General Meeting of Shareholders - The Globe and Mail
Boeing doesn't expect the US trade war with China to slow its recovery - The Globe and Mail
[WATCH] Trading Gaps: Spot Big Moves Before They Happen - The Globe and Mail
Limbach (LMB): Buy, Sell, or Hold Post Q4 Earnings? - The Globe and Mail
Where Will Nvidia Stock Be in 5 Years? - The Globe and Mail
Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC - The Globe and Mail
Viking Therapeutics Stock Pops But Struggles to Hold Gains - The Globe and Mail
CrowdStrike Stock is a Buy as Cyberthreat Environment Expands - The Globe and Mail
5 Top Psychedelic Stocks (2025) for Mental Health Investing - Securities.io
We're A Little Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Rate - Yahoo Finance
Metastatic Melanoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Google (GOOGL) Offers U.S. Government Major Discounts as It Challenges Microsoft - The Globe and Mail
Seeking High Dividend Yield? Earn 9.6% from This Energy Stock Now. - The Globe and Mail
Tetra Tech Awarded £36 Million Multiple-Award Contract for Water Infrastructure Services - The Globe and Mail
NESR to Participate in Water Tower Research Fireside Chat on April 10 at 11am ET - The Globe and Mail
Financial Survey: Vistagen Therapeutics (NASDAQ:VTGN) versus IO Biotech (NASDAQ:IOBT) - Defense World
WSP Global Inc. (TSE:WSP) Receives C$284.85 Consensus Target Price from Brokerages - Defense World
Evergy, Inc. (NASDAQ:EVRG) Receives $69.08 Average Price Target from Brokerages - Defense World
Brokerages Set Aspen Aerogels, Inc. (NYSE:ASPN) PT at $19.11 - Defense World
Ag Futures Markets Are Suffering a Severe Case of Tariff Indigestion. When Will They Rebound? - The Globe and Mail
Prediction: This Artificial Intelligence (AI) Semiconductor Stock Could Start Soaring After April 16 - The Globe and Mail
Q1 Earnings Forecast for IO Biotech Issued By HC Wainwright - Defense World
Globus Medical acquires Nevro Corp. - Medical Buyer
NeuroOne Medical Technologies commences proposed underwritten RPO - Medical Buyer
10 Best Healthcare Stocks to Invest In (May 2025) - Securities.io
IO Biotech (NASDAQ:IOBT) Given “Buy” Rating at HC Wainwright - Defense World
Fresh Quarter, Fresh Momentum? Markets Eye April 2nd Tariff Announcement - The Globe and Mail
IO Biotech Inc. (IOBT) reports earnings - qz.com
New PM2 Gene Discovery by Aurora Cannabis Enhances Disease Resistance - Securities.io
Alcon acquires majority stake in Aurion Biotech - Healio
IO Biotech secures over 400 million dkk in new capital - Dansk Industri
IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting - The Manila Times
IO Biotech Announces Acceptance Of Abstracts To Be Presented At The 2025 American Association For Cancer Research (AACR) Annual Meeting - MarketScreener
17.27%
1.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):